PURPOSE: Bladder carcinoma is the most common urological malignancy in China. Gene mutation may be one of causes of carcinogenesis in the cancer. We therefore investigated the mRNA expression of RTKN gene in clinic malignant bladder carcinoma and explored the relationship between the novel gene and the cancer. METHODS: Total RNA was extracted from 33 surgically resected specimens of bladder carcinoma and 19 specimens of tumor-free bladder tissues. After the optimal reverse-transcription polymerase chain reaction condition was established, the mRNA expression levels of the RTKN gene in the lesions and tumor-free bladder tissues were examined semiquantitatively, and the relationships between expression levels of RTKN and clinical pathological features were analyzed. RESULTS: The expression of RTKN gene mRNA in 33 human bladder carcinoma tissues was significantly higher than that in 19 human tumor-free bladder tissues (0.937+/-0.103 vs. 0.350+/-0.082). The average ratio of RTKN expression in neoplasms to that in tumor-free bladder tissues was 0.350+/-0.164. Based on this ratio the 33 patients were divided into three groups: a down-regulated expression group (n=2), an up-regulated expression group (n=22), and an unchanged group (n=9). Although the chi(2) test demonstrated a statistically nonsignificant differences in RTKN expression between tumor stages Ta, T(1), and T(2) overall in the 33 human bladder carcinoma, the t test showed that there were statistically significant differences between solitary and multiple tumors, between the paired group aged younger or older than 70 years in 27 de novo bladder carcinoma patients, and between the groups with tumor larger or smaller than 2.25 cm(3). CONCLUSIONS: These results suggest that the RTKN gene is involved in bladder carcinogenesis and progression in bladder carcinoma, indicating that RTKN gene could be a molecular target in cancer therapy.
PURPOSE:Bladder carcinoma is the most common urological malignancy in China. Gene mutation may be one of causes of carcinogenesis in the cancer. We therefore investigated the mRNA expression of RTKN gene in clinic malignant bladder carcinoma and explored the relationship between the novel gene and the cancer. METHODS: Total RNA was extracted from 33 surgically resected specimens of bladder carcinoma and 19 specimens of tumor-free bladder tissues. After the optimal reverse-transcription polymerase chain reaction condition was established, the mRNA expression levels of the RTKN gene in the lesions and tumor-free bladder tissues were examined semiquantitatively, and the relationships between expression levels of RTKN and clinical pathological features were analyzed. RESULTS: The expression of RTKN gene mRNA in 33 humanbladder carcinoma tissues was significantly higher than that in 19 humantumor-free bladder tissues (0.937+/-0.103 vs. 0.350+/-0.082). The average ratio of RTKN expression in neoplasms to that in tumor-free bladder tissues was 0.350+/-0.164. Based on this ratio the 33 patients were divided into three groups: a down-regulated expression group (n=2), an up-regulated expression group (n=22), and an unchanged group (n=9). Although the chi(2) test demonstrated a statistically nonsignificant differences in RTKN expression between tumor stages Ta, T(1), and T(2) overall in the 33 humanbladder carcinoma, the t test showed that there were statistically significant differences between solitary and multiple tumors, between the paired group aged younger or older than 70 years in 27 de novo bladder carcinomapatients, and between the groups with tumor larger or smaller than 2.25 cm(3). CONCLUSIONS: These results suggest that the RTKN gene is involved in bladder carcinogenesis and progression in bladder carcinoma, indicating that RTKN gene could be a molecular target in cancer therapy.
Authors: Celina G Kleer; Kenneth L van Golen; Yanhong Zhang; Zhi-Fen Wu; Mark A Rubin; Sofia D Merajver Journal: Am J Pathol Date: 2002-02 Impact factor: 4.307
Authors: H Suwa; G Ohshio; T Imamura; G Watanabe; S Arii; M Imamura; S Narumiya; H Hiai; M Fukumoto Journal: Br J Cancer Date: 1998 Impact factor: 7.640
Authors: Ganesh V Pusapati; Tim Eiseler; An Rykx; Sandy Vandoninck; Rita Derua; Etienne Waelkens; Johan Van Lint; Götz von Wichert; Thomas Seufferlein Journal: J Biol Chem Date: 2012-01-06 Impact factor: 5.157
Authors: F Perrier; V Viallon; S Ambatipudi; A Ghantous; C Cuenin; H Hernandez-Vargas; V Chajès; L Baglietto; M Matejcic; H Moreno-Macias; T Kühn; H Boeing; A Karakatsani; A Kotanidou; A Trichopoulou; S Sieri; S Panico; F Fasanelli; M Dolle; C Onland-Moret; I Sluijs; E Weiderpass; J R Quirós; A Agudo; J M Huerta; E Ardanaz; M Dorronsoro; T Y N Tong; K Tsilidis; E Riboli; M J Gunter; Z Herceg; P Ferrari; I Romieu Journal: Clin Epigenetics Date: 2019-04-02 Impact factor: 6.551